Why Britain's Pharmacy Body Ended Its Teva Sponsorship Deal
The Royal College of Pharmacy has dropped Teva UK as a sponsor and exhibitor for its annual conference next month.
The decision was reported on 9 October 2026. It makes pharmacy the second British health profession body within a week to end a commercial relationship with the British arm of Teva Pharmaceuticals, an Israeli drug company. The College is the professional body for Britain's 34,000 pharmacists. The Guardian
Teva UK was due to exhibit at four College events under a £15,000 deal. That included the Royal College of Pharmacy Annual Conference 2026, scheduled for 6 November in London and online. The company will now have no sponsorship or exhibition presence at that meeting.
The College said its decision followed a further due diligence review, a formal background check on a partner, which brought to its attention the possibility of certain Teva Pharmaceuticals activities which do not align with its values. It did not name specific conduct.
Campaign pressure came before the outcome. Campaigners including UK Healthcare Petitions to Royal Colleges circulated an open letter demanding cancellation of Teva sponsorship and exhibition at the 2026 conference. Teva said it was disappointed at being dropped and that healthcare should not become politicised.
The pharmacy decision followed action by the Royal College of Nursing. The nursing college, the professional body representing 500,000 UK nurses and described as the world's largest nursing union, last week cut its longstanding ties with Teva UK. It dropped the company as a sponsor of both the union and an event on headache and migraine.
Teva UK will no longer be a sponsor of the RCNi nursing leadership summit: migraine and headache services event, scheduled for 30 October 2026. The Guardian That paper reported the nursing union ended Teva UK as a commercial partner over links to Israel's military and corporate track record. Haaretz described the nursing cancellation as following pressure from pro-Palestinian groups.
There is institutional precedent for ethics-based divestment, or pulling money out on ethical grounds. The Royal College of Pharmacy's predecessor, the Royal Pharmaceutical Society, responded to Russia's 2022 invasion of Ukraine by no longer investing money in funds involving Russian firms.
The broader context here is how professional bodies manage paid partnerships under political scrutiny. Sponsorship and exhibition deals are routine revenue for conferences, like renting stalls at a trade fair. They also create reputational exposure. Due diligence reviews offer a procedural route to exit such deals without adopting the language of campaigners. That distinction between values language and political language will be familiar from university, pension fund and medical association debates.
Looking ahead to what this could mean for conference organisers, the sequence from nursing to pharmacy shows how one break lowers the cost of a second. Campaign groups learn which tactics produce results, such as open letters and targeted sponsorship demands. Corporate sponsors recalculate. The open question is whether other health bodies apply similar reviews to existing exhibitor lists, and whether Teva seeks other routes to clinical engagement. Clinical programming stays intact, but its funding and foyer change. Pressure of this kind rarely aims to alter prescribing guidance directly. It aims to restrict institutional legitimacy and visibility.
